Consequently, miR-326 acts as a negative regulator of CD155 expression in lung adenocarcinoma, and as a result, it may have a role in the emergence of resistance to PD-1/PD-L1 inhibitors [181]. The gene discussed is PDCD1; the disease is lung adenocarcinoma.